Effect of fenofibrate on Chlamydia pneumoniae antibody levels in patients with coronary artery disease.
Mark
Laszlo
L
Katona
Andras
A
Marki-Zay
Janos
J
D000907:Antibodies, Bacterial / Q000097:blood / Q000187:drug effects*; D016632:Apolipoprotein A-I / Q000097:blood / Q000187:drug effects; D001055:Apolipoproteins B / Q000097:blood / Q000187:drug effects; D016993:Chlamydophila pneumoniae / Q000276:immunology*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D011345:Fenofibrate / Q000494:pharmacology* / Q000627:therapeutic use; D005340:Fibrinogen / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017270:Lipoprotein(a) / Q000097:blood / Q000187:drug effects; D008074:Lipoproteins / Q000097:blood / Q000187:drug effects*; D014280:Triglycerides / Q000097:blood
D000907:Antibodies, Bacterial; D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D017270:Lipoprotein(a); D008074:Lipoproteins; D014280:Triglycerides; D005340:Fibrinogen; D002784:Cholesterol; D011345:Fenofibrate